

[Open Peer Review on Qeios](#)

Daclizumab

National Cancer Institute

Source

National Cancer Institute. *Daclizumab*. NCI Thesaurus. Code C1569.

A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.